OptiHealth Products, Inc. – FDA Warning Letter, Dec 1, 2025

OptiHealth Products, Inc. received a formal warning letter from the FDA on April 29, 2026, following a review of the company"s website and social media presence in December 2025. The regulatory agency determined that the company’s product, Super Antioxidant (OPCXtra), is marketed with claims that classify it as a drug under the Federal Food, Drug, and Cosmetic Act. Specifically, the FDA identified marketing materials suggesting the product can treat, mitigate, or prevent serious medical conditions, including heart disease, diabetes, chronic inflammation, Alzheimer’s disease, Parkinson’s disease, and age-related macular degeneration. Under federal law, products intended for such uses are considered "new drugs" and require scientific data and FDA approval to prove safety and effectiveness before they can be sold. Because Super Antioxidant (OPCXtra) lacks this approval, its distribution violates federal law. Furthermore, the FDA classified the product as misbranded because it fails to provide adequate directions for use. Since the targeted conditions require the supervision of a licensed healthcare practitioner, it is impossible to provide instructions that would allow a layperson to use the product safely for these purposes. OptiHealth Products, Inc. is required to respond to the FDA within 15 working days of receiving the letter. The response must outline the specific actions taken to correct the violations and explain the steps implemented to prevent future occurrences. Failure to address these concerns adequately may result in legal action, such as product seizure or a court-ordered injunction.